Print  |  Close

Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Active: Yes
Cancer Type: Unknown Primary NCT ID: NCT01656603
Trial Phases: Phase II Protocol IDs: 6637-01 (primary)
Eligibility: 0 Years and older, Male and Female Study Type: Treatment
Study Sponsor: New York Blood Center
NCI Full Details:


This study will evaluate the safety of infusion of the investigational cord blood units
by carefully documenting all infusion-related problems.


The primary aim of this study is to examine the safety of administration of the
unlicensed investigational NCBP hematopoietic progenitor cell-cord blood (HPC-CORD BLOOD)
products in a multi-institution setting. Therefore, the study will evaluate prospectively
the incidence of serious adverse reactions as well as the incidence of all infusion
related reactions after administration of the unlicensed, investigational NCBP CBU.

Definitions of Infusion-related adverse reactions:

Mild - Moderate: reactions during or after the infusion of the cord blood (CB) product
that require some medical intervention but do not affect the overall patient status or

Severe: serious, life-threatening or fatal infusion reactions, requiring major medical
intervention. These include: anaphylactic shock, acute cardiac, pulmonary or renal
failure, seizures, patient transfer to the Intensive Care Unit, or death within 48 hours
of the CB infusion. Adverse Reactions will also be classified by grade, according to the
Common Terminology Criteria for Adverse Events v4.0 (CTCAE).

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.